Table 3 Risk of AF in different groups/levels of the TyG index
Study | Year | Population | Group 1 | Group 2 | Group 3 | Group 4 | Continuous |
|---|---|---|---|---|---|---|---|
Population-based cohorts | |||||||
 Liu et al | 2023 | Population-based cohort of 15,792 patients aged 45 to 64 from 4 US communities | TyG < 8.8 [aHR 1.15] [95% CI 1.02 to 1.29]* | 8.8 < TyG < 9.2 [Ref] | 9.2 < TyG [aHR 1.18] [95% CI 1.03 to 1.37]* | – | – |
 Muhammad et al | 2022 | General population | Q1 [Ref] | Q2 [aHR 1.02] [95% CI 0.95 to 1.09] | Q3 [aHR 0.97] [95% CI 0.9 to 1.04] | Q4 [aHR 0.96] [95% CI 0.89 to 1.04] | Per 1-unit increase [aHR 0.99] [95% CI 0.89 to 1.11] |
Coronary artery disease | |||||||
 Ling et al | 2022 | ST-Segment Elevation Myocardial Infarction Patients After Percutaneous Coronary Intervention | – | – | – | – | Per 1-unit increase [OR 8.884] [95% CI 1.57 to 50.265]*** |
Non-alcoholic fatty liver disease | |||||||
 Zhang et al | 2023 | Patients diagnosed with NAFLD by ultrasound | Q1 [Ref] | Q2 [OR 1.2] [95% CI 0.66 to 2.17] | Q3 [OR 1.93] [95% CI 1.07 to 3.49]* | Q4 [OR 4.34] [95% CI 2.37 to 7.94]*** | Per 1-unit increase [OR 4.84] [95% CI 2.98 to 7.88]*** |
Atrial fibrillation recurrence | |||||||
 Tang et al | 2022 | Patients with AF who underwent RFCA | – | – | – | – | Per 1-unit increase [HR 2.015] [95% CI 1.408 to 4.117]** |